Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor...

Area of Science:

• Oncology
• Medicinal Chemistry
• Hematology

Background:

• FMS-like tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia (AML) and associated with poor prognosis.
• FLT3 inhibitors represent a therapeutic strategy for AML, necessitating the development of novel agents.

Purpose of the Study:

• To discover and characterize novel pyrazole amine derivatives as potent FLT3 inhibitors.
• To evaluate the efficacy and safety of lead compounds in preclinical AML models.

Main Methods:

• Synthesis and screening of pyrazole amine compounds for FLT3 inhibitory activity.
• In vitro assays assessing FLT3 autophosphorylation, STAT5 phosphorylation, and apoptosis in AML cell lines (MV4-11).
• In vivo studies using MV4-11 xenograft models to evaluate tumor growth suppression, metabolic stability, and toxicity.

Main Results:

• A series of pyrazole amine compounds demonstrated potent FLT3-ITD inhibition and selectivity.
• Compound 46 effectively blocked FLT3 signaling, induced apoptosis, and downregulated p-STAT5 in vitro.
• Compound 46 exhibited metabolic stability, significantly suppressed tumor growth in vivo, and showed no observable toxicity in mice.

Conclusions:

• Compound 46 is a promising drug candidate with potent FLT3 inhibitory activity and favorable preclinical safety profile.
• The discovered pyrazole amine scaffold offers valuable insights for developing new FLT3 inhibitors for AML treatment.